Enfusion Inc. (ENFN)
NYSE NYSE Primary 
Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy
I am upgrading Clearwater Analytics to a 'Strong Buy' due to their strategic acquisitions and robust fundamentals, despite recent stock price fluctuations. Clearwater's acquisition of Enfusion, Beacon, and Bistro significantly enhances their product offerings and positions them as a comprehensive solution provider in the financial software industry. The Enfusion deal, valued at $1.5 billion, adds $200 million ARR and expands Clearwater's capabilities into front office functions, addressing a critical gap.
Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates
Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.
Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock
Piper Sandler analyst Arvind Ramnani upgraded the shares of Clearwater Analytics Holdings Inc CWAN from Neutral to Overweight and raised the price forecast from $28.00 to $36.00.
Enfusion, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Enfusion Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board breached its fiduciary duties to shareholders.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
BofA moves to No Rating on Enfusion after Clearwater Analytics deal
Enfusion +0.84 (+8.41%) Clearwater Analytics -1.48 (-5.47%)
Clearwater agrees to buy investment management platform Enfusion for $1.5B
Clearwater Analytics, a company developing accounting, compliance, and risk reporting tools for asset managers, said on Monday it has entered into a definitive agreement to acquire investment management platform Enfusion for $1.5 billion.
Clearwater Analytics to acquire Enfusion in $1.5 bln deal
Clearwater Analytics has agreed to acquire investment management platform Enfusion in a $1.5 billion cash-and-stock deal, the companies said on Monday.
Enfusion: Revenue Growth Should Start To Accelerate
I maintain a buy rating for ENFN, anticipating revenue growth to exceed 20% due to improving macro conditions and solid execution. The macro environment has shown signs of turnaround, with rate cuts and reduced election uncertainty, boosting demand sentiment. ENFN's strong execution is evident in stable front book revenue growth, customer additions, and successful upmarket penetration.
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript
Enfusion, Inc. (NYSE:ENFN ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - Chief Executive Officer Bradley Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Dylan Becker - William Blair Parker Lane - Stifel Kevin McVeigh - UBS Elise Kenner - JP Morgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Crispin Love - Piper Sandler Operator Good morning, ladies and gentlemen. Thank you for standing by.
Here's What Key Metrics Tell Us About Enfusion (ENFN) Q3 Earnings
The headline numbers for Enfusion (ENFN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
